Van ECK Associates Corp Purchases 315 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Van ECK Associates Corp grew its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 47.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 985 shares of the company’s stock after acquiring an additional 315 shares during the period. Van ECK Associates Corp’s holdings in Omnicell were worth $44,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMCL. KBC Group NV raised its stake in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares in the last quarter. 1620 Investment Advisors Inc. grew its holdings in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the period. Summit Global Investments purchased a new stake in Omnicell in the third quarter worth about $221,000. QRG Capital Management Inc. purchased a new stake in shares of Omnicell during the third quarter valued at approximately $231,000. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Omnicell during the third quarter valued at approximately $249,000. 97.70% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is owned by corporate insiders.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $39.72 on Monday. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a market capitalization of $1.84 billion, a P/E ratio of 147.12, a PEG ratio of 7.53 and a beta of 0.78. The firm has a fifty day simple moving average of $42.96 and a two-hundred day simple moving average of $43.86. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on OMCL. Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. increased their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Benchmark reaffirmed a “buy” rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $52.33.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.